Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
BMS grows immunology portfolio with IFM deal
by Lisa Jarvis
August 20, 2017
| A version of this story appeared in
Volume 95, Issue 33
Bristol-Myers Squibb will pay $300 million up front to acquire IFM Therapeutics, a developer of small-molecule drugs that target the innate immune system, the body’s first line of immunological defense. IFM investors could receive up to $1 billion more if the company’s lead molecules reach the market. BMS has been amassing immunology and immuno-oncology compounds, but they try to harness primarily the adaptive immune system. With this deal, BMS gains two preclinical cancer programs—NLRP3 agonists and STING agonists—intended to amp up innate immune response.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter